Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Pharmaceutical firm Eli Lilly made a $10m equity investment in UK-based immunometabolic drug developer Sitryx on Tuesday as part of a licensing and research collaboration deal involving a $50m upfront payment and up to $820m in milestone payments. Sitryx closed a $30m series A round in late 2018 that was co-led by SV Health Investors and Sofinnova Partners, and backed by pharmaceutical firm GlaxoSmithKline and Longwood Fund following an undisclosed amount of seed capital from SV Health,
IN Venture,…
